Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Eli Lilly's Q3 Results Expected to Meet Estimates as Mounjaro Outperforms, Deutsche Bank Says
08.10.2025 14:59
Eli Lilly (LLY) is projected to report Q3 results broadly in line with Wall Street expectations, dri
Ex-FDA chief Peter Marks joins Eli Lilly’s infectious disease unit
08.10.2025 14:43
Marks is now the second high-ranking former FDA employee Lilly has snapped up in the last month.
Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875
08.10.2025 14:02
Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when Guggenheim reaffirmed its Buy rating with a price target of $875. The analyst noted that there was strong demand for tirzepatide […]
HealthTap Expands Access to Primary Care-Driven Diabetes Treatment Through LillyDirect®
08.10.2025 12:00
SUNNYVALE, Calif., October 08, 2025--HealthTap, a leading virtual healthcare provider delivering accessible, high-quality virtual primary care, today announced it will be listed as the latest independent care provider option on Eli Lilly and Company’s digital healthcare platform, LillyDirect® , expanding access to primary care-driven diabetes management. With this news, HealthTap becomes the first primary care telehealth practice accessible via LillyDirect®.
These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030
08.10.2025 10:31
Investors should buy stakes in AI-powered stocks with scalable, asset-light business models.
Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations
08.10.2025 07:00
LONDON, October 08, 2025--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
07.10.2025 06:14
Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. See why NVO stock is a Buy now.
Eli Lilly's $1 Billion India Gamble Signals Pharma's Next Global Power Shift
06.10.2025 18:57
As Trump's drug tariffs bite, Lilly doubles down on India to secure its manufacturing future
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
06.10.2025 14:11
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
06.10.2025 13:29
Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma players.
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
06.10.2025 13:03
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback
06.10.2025 12:26
Novo Nordisk A/S faces competition in obesity drug development space; pipeline innovations & long-term outlook. Read why NVO stock is downgraded to Buy.
Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy
06.10.2025 11:35
Trogenix’s platform uses an AAV packed with two payloads in a “Trojan horse” approach to cancer treatment.
Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
06.10.2025 11:30
LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the treatment of adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.1 This indication was a
4BIO Capital founded Trogenix secures £70 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
06.10.2025 11:05
Trogenix was founded by 4BIO as a spinout from the University of Edinburgh alongside Professor Steve Pollard and Dr Ken Macnamara in 2023Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers£70 million financing round led by IQ Capital with participation from new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital London, United Kingdom, 6 O
Eli Lilly to invest over $1 billion in India in global expansion
06.10.2025 10:30
STORY: Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers. That’s according to the pharmaceutical giant Monday. It wants to tap into a skilled workforce to bolster its global manufacturing expansion.The company said collaborations aim to increase the availability of Lilly's key drugs.This includes those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions.The company launched its blockbuster weight-loss drug Mounjaro in India this year.But it doesn’t currently operate its own manufacturing plant in the country. Lilly's investment plans in India come at a time when global drugmakers are rushing to boost U.S. manufacturing capacity.That’s after the Trump administration imposed a 100% tariff on imported branded drugs from October 1.Last month, Lilly itself announced a $5 billion investment in a new Virginia facility, part of its $27 billion five-year U.S. expansion plan.Meanwhile, its India launch of Mounjaro has helped increase awareness of obesity treatments…In a country projected to have the world's second-largest obese population by 2050.Sales there of both Mounjaro and rival Novo Nordisk’s Wegovy doubled within months of their launch.
The Healthcare Stock Play That Could Make Millennials Rich
06.10.2025 09:54
This investment may also make baby boomers, and those from Gen X and Gen Z, rich as well.
Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
06.10.2025 06:00
Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancersFinancing round led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the National Brain Tumor Society’s Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus CapitalCancer Research Horizons’ la